BioSpace News Archive

IRVINE, Calif. and AMSTERDAM , Feb. 18, 2020 /PRNewswire/ -- Agendia, Inc. , a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt trial. The study measured changes in both treatment decisions and physician confidence when using the MammaPrint® and BluePrint® assays to support medical management for patie

Cozeva (Cozeva.com), a provider of software solutions to health systems, announced an innovative approach to submitting the Annual Wellness Visit (AWV) and Practitioner Assessment Form (PAF) in Cozeva’s provider portal.

VisiQuate Inc. announced that the University of Chicago Medicine has finalized a multi-year agreement with VisiQuate to deploy advanced analytics.

Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot, state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina

The Global Virus Network (GVN), representing 53 Centers of Excellence and 9 Affiliates in 32 countries comprising foremost experts in every class of virus causing disease in humans and some animals, is holding regular strategic discussions with its members regarding the COVID-19 outbreak, which originated in Wuhan, China this past December

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, at 1:30 p.m. E.T.

The Quell Foundation is proud to announce that it received a grant from the AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting health-related causes that enrich the global community.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results after the close of U.S. financial markets on Tuesday, February 25, 2020

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors.

Cytokinetics, Incorporated announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time.